Federal prosecutors open criminal probe into MLBPA's Players Way venture amid allegations of self-dealing and misuse of union resources.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier $4.9 billion deal and intensifying the race for dominance in the lucrative obesity drug market.
Altria's Q3 earnings beat estimates, but shares fell on a weak outlook and persistent industry challenges.
Federal prosecutors open criminal probe into MLBPA's Players Way venture amid allegations of self-dealing and misuse of union resources.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier $4.9 billion deal and intensifying the race for dominance in the lucrative obesity drug market.
Altria's Q3 earnings beat estimates, but shares fell on a weak outlook and persistent industry challenges.